T-DM1 for HER2 positive advanced breast cancer: a single institution, "real life" experience

被引：0
|
作者：
Bertolini, I. [1 ,2 ,3 ]
Ferrarini, I. [1 ,2 ,3 ]
Fancelli, S. [1 ,2 ,3 ]
De Angelis, C. [1 ,2 ,3 ]
Fontana, A. [1 ,2 ,3 ]
Salvadori, B. [1 ,2 ,3 ]
Landucci, E. [2 ,3 ,4 ]
Michelotti, A. [2 ,3 ,4 ]
Falcone, A. [1 ,2 ,3 ]
机构：
[1] UO Oncol Med II Univ, Pisa, Italy
[2] Osped S Chiara, AOUP, Polo Oncol, Pisa, Italy
[3] Ist Toscano Tumori, Pisa, Italy
[4] UO Oncol Med I, Pisa, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A59
引用
收藏
页码：20 / 21
页数：2
相关论文
共 50 条
  • [1] Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature
    Martinez, Maria Teresa
    Perez-Fidalgo, Jose Alejandro
    Martin-Martorell, Paloma
    Cejalvo, Juan Miguel
    Pons, Vanesa
    Bermejo, Begona
    Martin, Miguel
    Albanell, Joan
    Lluch, Ana
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 97 : 96 - 106
  • [2] Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience
    Okines, Alicia
    Irfan, Tazia
    Khabra, Komel
    Smith, Ian
    O'Brien, Mary
    Parton, Marina
    Noble, Jill
    Stanway, Susie
    Somaiah, Navita
    Ring, Alistair
    Johnston, Stephen
    Turner, Nicholas
    [J]. BREAST JOURNAL, 2018, 24 (03): : 253 - 259
  • [3] Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience
    Omarini, C.
    Medici, G.
    Guaitoli, G.
    Iattoni, E.
    Moscetti, L.
    Balduzzi, S.
    Cascinu, S.
    Piacentini, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [4] Central nervous system (CNS) disease during trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer (ABC): A single institution experience
    Irfan, T.
    Turner, N. M.
    Johnston, S.
    Smith, I.
    O'Brien, M.
    Parton, M.
    Ring, A.
    Noble, J.
    Stanway, S.
    Somaiah, N.
    Khabra, K.
    Okines, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] Italian observational study on T-DM1 in HER2 positive advanced breast cancer patients: real world effectiveness and safety
    Fabi, A.
    Alesini, D.
    De laurentiis, M.
    Valle, E.
    Santini, D.
    Cannita, K.
    Carbognin, L.
    Ciccarese, M.
    Arpino, G.
    Leonardi, V.
    Montemurro, F.
    La Verde, N.
    Generali, D. G.
    Scandurra, G.
    Russillo, M.
    Paris, I.
    D'Ottavio, A. M.
    Filippelli, G.
    Stani, S.
    Giannarelli, D.
    Cognetti, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    [J]. ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [7] Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
    Bon, Giulia
    Pizzuti, Laura
    Laquintana, Valentina
    Loria, Rossella
    Porru, Manuela
    Marchio, Caterina
    Krasniqi, Eriseld
    Barba, Maddalena
    Maugeri-Sacca, Marcello
    Gamucci, Teresa
    Berardi, Rossana
    Livi, Lorenzo
    Ficorella, Corrado
    Natoli, Clara
    Cortesi, Enrico
    Generali, Daniele
    La Verde, Nicla
    Cassano, Alessandra
    Bria, Emilio
    Moscetti, Luca
    Michelotti, Andrea
    Adamo, Vincenzo
    Zamagni, Claudio
    Tonini, Giuseppe
    Barchiesi, Giacomo
    Mazzotta, Marco
    Marinelli, Daniele
    Tomao, Silverio
    Marchetti, Paolo
    Valerio, Maria Rosaria
    Mirabelli, Rosanna
    Russo, Antonio
    Fabbri, Maria Agnese
    D'Ostilio, Nicola
    Veltri, Enzo
    Corsi, Domenico
    Garrone, Ornella
    Paris, Ida
    Sarobba, Giuseppina
    Giotta, Francesco
    Garufi, Carlo
    Cazzaniga, Marina
    Del Medico, Pietro
    Roselli, Mario
    Sanguineti, Giuseppe
    Sperduti, Isabella
    Sapino, Anna
    De Maria, Ruggero
    Leonetti, Carlo
    Di Leo, Angelo
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [8] Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
    Giulia Bon
    Laura Pizzuti
    Valentina Laquintana
    Rossella Loria
    Manuela Porru
    Caterina Marchiò
    Eriseld Krasniqi
    Maddalena Barba
    Marcello Maugeri-Saccà
    Teresa Gamucci
    Rossana Berardi
    Lorenzo Livi
    Corrado Ficorella
    Clara Natoli
    Enrico Cortesi
    Daniele Generali
    Nicla La Verde
    Alessandra Cassano
    Emilio Bria
    Luca Moscetti
    Andrea Michelotti
    Vincenzo Adamo
    Claudio Zamagni
    Giuseppe Tonini
    Giacomo Barchiesi
    Marco Mazzotta
    Daniele Marinelli
    Silverio Tomao
    Paolo Marchetti
    Maria Rosaria Valerio
    Rosanna Mirabelli
    Antonio Russo
    Maria Agnese Fabbri
    Nicola D’Ostilio
    Enzo Veltri
    Domenico Corsi
    Ornella Garrone
    Ida Paris
    Giuseppina Sarobba
    Francesco Giotta
    Carlo Garufi
    Marina Cazzaniga
    Pietro Del Medico
    Mario Roselli
    Giuseppe Sanguineti
    Isabella Sperduti
    Anna Sapino
    Ruggero De Maria
    Carlo Leonetti
    Angelo Di Leo
    [J]. Journal of Experimental & Clinical Cancer Research, 39
  • [9] T-DM1 for HER2-positive metastatic breast cancer
    Yaqub, Farhat
    [J]. LANCET ONCOLOGY, 2013, 14 (03): : E94 - E94
  • [10] Concomitant Association of T-DM1 and Radiation: An In Vitro Study on HER2 Positive Cells of Breast Cancer
    Mignot, F.
    Verrelle, P.
    Kirova, Y.
    Megnin-Chanet, F.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E186 - E186
12345